Loading stock data…
Personalis (PSNL)
$13.75+0.73 (+5.61%)
Market ClosedLast close Jun 29
Personalis, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Personalis, Inc. in the Healthcare sector is trading at $13.75 with a market capitalization of $1.0B. Wall Street consensus targets $10.86 (7 analysts), implying a -21.0% move over the next 12 months. The stock is currently near its 52-week high of $14.07, remaining 66.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -21.0% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.47M↓ | $17.34M↑ | $14.49M↓ | $17.20M↓ | $20.61M |
| Gross Profit | $281,000↓ | $1.90M↓ | $1.91M↓ | $4.76M↓ | $7.21M |
| Operating Income | -$32.16M↓ | -$25.27M↓ | -$23.29M↓ | -$21.80M↓ | -$17.70M |
| Net Income | -$30.03M↓ | -$23.81M↓ | -$21.65M↓ | -$20.06M↓ | -$15.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.51%
Volume
Today's trading volume
3.77M
Recent News
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
This cancer genomics specialist, serving major biopharma and research clients, reported a notable insider sale in its latest SEC filing.
Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum
Why Personalis Stock Is On Investors’ Radar Personalis (PSNL) has been drawing fresh attention after a strong run in the past month, with the stock also showing solid gains over the past 3 months and year to date. See our latest analysis for Personalis. Personalis’ recent surge, including a 34.6% 7 day share price return and 97.2% 30 day share price return, sits alongside a 1 year total shareholder return of 136%, signalling strong momentum after a mixed multi year picture. If you are...
Sector Update: Healthcare Stocks Mixed Late Afternoon
Healthcare stocks were mixed late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and th
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Quantum Cyber (NASDAQ:QUCY) shares increased by 55.0% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 21.26% to $6.33. The market value of their outstanding shares is at $963.2 million. The company's, Q1 earnings came out yesterday. Whitehawk Therapeutics (NASDAQ:WHWK) stock rose 20.17% to $4.71. The market value of their outstanding shares is at $193.8 million. As per
Personalis Q1 Earnings Call Highlights
Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business and biopharma MRD programs over lower-margin legacy enterprise revenue. Chief Executive Officer Chri